Scilex Holding Company Common Stock

SCLXNASDAQ • USD
0.65 USD
↘ 0.60 (47.70%)🟢LIVE (AS OF 11:41 AM EST)
🟢Market: OPEN

Scilex Holding Company Common Stock (SCLX) is currently trading at $0.65. The stock presents a bearish profile across the board: technical indicators signal "Sell" and our fundamental models agree with a "Sell" rating. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 1/9, exceptional Return on Equity (145.4%), a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.

Technical & fundamental data as of Nov 16, 2026.

Open?$1.23
High?$1.26
Low?$0.58
Prev. Close?$1.25
Volume?353.7K
Avg. Volume?45.9K
VWAP?$0.74
Rel. Volume?7.70x
Bid / Ask
Bid?$0.58 × 100
Ask?$0.80 × 100
Spread?$0.22
Midpoint?$0.69
Valuation & Ratios
Market Cap?8.8M
Shares Out?8.5M
Float?6.8M
Float %?80.0%
P/E Ratio?N/A
P/B Ratio?-0.03
EPS?-$63.73
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Employees
34
Market Cap
8.8M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
2022-11-11
Address
960 SAN ANTONIO ROAD
PALO ALTO, CA 94303
Phone: (650) 516-4310
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
6
Z-Score?
0
Momentum?
18
Short Sent.?
83
Piotroski F-Score?1/9Weak
Altman Z-Score?-12.75Distress
Confidence?46%Low
Full Fundamental Analysis →
Short InterestModerate
Short % of Float?1.95%Low
Short Interest?132.2K
Days to Cover?3.4
Free Float6.8M
Avg Daily Volume39.3K
Settlement Date2026-10-30
Financial Health
Current Ratio?0.07Weak
Quick Ratio?0.06Weak
Cash Ratio?0.00Low
Debt/Equity?-0.27Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
S&P
97
-0.03CHEAP▾
P/S?
Peers
100
S&P
97
0.28CHEAP▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-0.3CHEAP▾
EV/Sales?
Peers
100
S&P
62
2.89CHEAP▾
Returns & Efficiency
ROE?
Peers
50
S&P
97
145.4%STRONG▾
ROA?
S&P
3
-176.8%WEAK▾
Cash Flow & Enterprise
FCF?$-17811000
Enterprise Value?$91.3M
Fundamentals ratios updated end of day